

**NOTICE OF INTENT TO AMEND RULE IN THE GEORGIA STATE BOARD OF
PHARMACY RULES
CHAPTER 480-34, 480-34-.04 SYNTHETIC CANNABINOIDS AND
NOTICE OF PUBLIC HEARING**

TO ALL INTERESTED PERSONS AND PARTIES:

Notice is hereby given that pursuant to the authority set forth below, the Georgia State Board of Pharmacy (hereinafter "Board") proposes amendments to the Georgia Board of Pharmacy Rules, Rule 480-34-.04 SYNTHETIC CANNABINOIDS (hereinafter "proposed amendments").

This notice, together with an exact copy of the proposed amendments and a synopsis of the proposed amendments, is being forwarded to all persons who have requested, in writing, that they be placed on an interested parties list. A copy of this notice, an exact copy of the rule including the proposed amendments, and a synopsis of the rule including the proposed amendments may be reviewed during normal business hours of 8:00 a.m. to 5:00 p.m. Monday through Friday, except official State holidays, at the Department of Community Health at 2 Peachtree Street, NW, Atlanta, Georgia, 30303. These documents will also be available for review on the Georgia State Board of Pharmacy's web page at www.gbp.georgia.gov.

A public hearing is scheduled to begin at 9:00 AM on December 11, 2013 at the Georgia Board of Pharmacy, Department of Community Health, 2 Peachtree Street, 36th Floor, Atlanta, GA 30303 to provide the public an opportunity to comment upon and provide input into the proposed amendments. At the public hearing, anyone may present data, make a statement, comment or offer a viewpoint or argument whether orally or in writing. Lengthy statements or statements of a considerable technical or economic nature, as well as previously recorded messages, must be submitted for the official record. Oral statements should be concise and will be limited to 5 minutes per person. Additional comments should be presented in writing. Written comments are welcome. To ensure their consideration, written comments may be received prior to December 4, 2013. Written comments should be addressed to the Executive Director of the Georgia State Board of Pharmacy at 2 Peachtree Street NW, Atlanta, Georgia 30303 FAX: 678-717-6694. You may email your comments to tbattle@dch.ga.gov.

The proposed amendments will be considered for adoption by the Georgia State Board of Pharmacy at its conference call scheduled to begin at 3:00 PM on December 19, 2013 at the Georgia Board of Pharmacy, Department of Community Health, 2 Peachtree Street, 36th Floor, Atlanta, GA 30303. According to the Department of Law, State of Georgia, the Georgia State Board of Pharmacy has the authority to adopt the proposed amendments pursuant to authority contained in O.C.G.A. §§ 16-13-22, 16-13-25, 26-4-27 and 26-4-28.

At its meeting by conference call on November 19, 2013, the Board voted that the formulation and adoption of these rule amendments do not impose excessive regulatory cost on any licensee and any cost to comply with the proposed amendments cannot be reduced by a less expensive alternative that fully accomplishes the objectives of O.C.G.A §§ 26-4-27, 26-4-28, 16-13-22.


Also, at its meeting by conference call on November 19, 2013, the Board voted that it is not legal or feasible to meet the objectives of O.C.G.A §§ 26-4-27, 26-4-28, 16-13-22 to adopt or implement differing actions for businesses as listed at O.C.G.A§ 50-13-4(a)(3)(A), (B), (C) and (D). The

formulation and adoption of these amendments will impact every licensee in the same manner, and each licensee is independently licensed, owned and operated and dominant in the field of pharmacy.

For further information, contact the Board office at 404-651-8000.

This notice is given in compliance with O.C.G.A. §50-13-4.

This 19th day of November, 2013


Tanja D. Battle
Executive Director
Georgia Board of Pharmacy

Posted: November 19th, 2013

**SYNOPSIS OF PROPOSED AMENDMENTS OF THE
GEORGIA STATE BOARD OF PHARMACY RULES
CHAPTER 480-34, 480-34-.04 SYNTHETIC CANNABINOIDS**

Purpose of Rule: The purpose of this rule is to protect the health, safety, and welfare of the public. At its meeting on September 18, 2013, the Board adopted an emergency rule to add the drugs listed in this proposed rule amendment to the Schedule I drug list.

Main Features: The main feature of this rule is to identify new compounds of Synthetic Cannabinoids as Schedule I substances under the Georgia Controlled Substances Act and to add them to the Pharmacy Board Rule regarding Synthetic Cannabinoids.

**DIFFERENCES OF THE PROPOSED AMENDMENTS FOR THE
GEORGIA STATE BOARD OF PHARMACY RULES
CHAPTER 480-34, 480-34-.04 SYNTHETIC CANNABINOIDS**

NOTE: Struck through text is proposed to be deleted. Underlined text is proposed to be added.

480-34-.04 Synthetic Cannabinoids.

(1) This rule was adopted to protect the health, safety, and welfare of the public. This rule places newly identified compounds, including any material, compound, mixture, or preparation which contains these substances or their derivatives, salts, isomers, or salts of isomers, halogens, analogues, and/or homologues, collectively known as Synthetic Cannabinoids, under Schedule I, of the Georgia Controlled Substances Act, Code Section 16-13-25 (12) as follows:

(M) (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl) methanone (UR-144)

(N) [1-(5-fluoropentyl)indole-3yl]-(2,2,3,3-tetramethylcyclopropyl) methanone (XLR11)

(O) [1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester (URB602)

(P) [1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl) methanone (A-796,260)

(Q) [3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate (URB597).

(R) 6-methyl-2-[(4-methylphenyl)amino]-1-benzoxazin-4-one (URB754)

(S) 1-pentyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indazole-3-carboxamide (AKB48)

(T) 1-pentyl-3-(1-adamantylamido)indole (2NE1)

(U) 1-(5-fluoropentyl)-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indole-3-carboxamide (STS-135)

(V) 1-naphthalenyl[4-(pentylox)-1-naphthalenyl]-methanone (CB-13)

(W) (1-(5-chloropentyl)indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (5-Chloro-UR-144)

(X) (1-(5-bromopentyl)indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (5-Bromo-UR-144)

(Y) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (ADBICA)

(Z) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5-Fluoro-ADBICA)

(2) This rule is based on the following findings of the Board:

(a) that Synthetic Cannabinoids have an extremely high potential for abuse;

- (b) that scientific evidence and scientific knowledge of the pharmacological effects of these compounds demonstrate that the public is at extreme risk if they are not regulated as controlled substances;
- (c) that the pattern of abuse of these compounds and the scope and significance of that abuse support regulation;
- (d) that there exists an imminent peril to the public health and welfare with regard to the abuse of these compounds;
- (e) that these compounds have the same risk to the public health of citizens of the State of Georgia as other substances already contained in Schedule I under the Controlled Substances Act;
- (f) that these compounds have no known precursor already scheduled under the Act; and
- (g) that the DEA encourages all states to add these compounds to their respective Controlled Substances Acts while DEA follows its procedures to add such compounds to the Federal Controlled Substances Act under Schedule I.

Authority: O.C.G.A. §§ 16-13-22, 16-13-25, 26-4-27 and 26-4-28.